Found: 14
Select item for more details and to access through your institution.
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1247879
- By:
- Publication type:
- Article
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non--Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2014, v. 15, n. 6, p. 418, doi. 10.1016/j.cllc.2014.06.007
- By:
- Publication type:
- Article
Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.
- Published in:
- 2013
- By:
- Publication type:
- Journal Article
Pemetrexed Use in the Adjuvant Setting for Completely Resectable Non—Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2013, v. 14, n. 6, p. 601, doi. 10.1016/j.cllc.2013.06.001
- By:
- Publication type:
- Article
Association between Gene Expression Profiles and Clinical Outcome of Pemetrexed-Based Treatment in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Exploratory Results from a Phase II Study.
- Published in:
- PLoS ONE, 2014, v. 9, n. 9, p. 1, doi. 10.1371/journal.pone.0107455
- By:
- Publication type:
- Article
TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR -Mutant Non-Small Cell Lung Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 24, p. 6127, doi. 10.3390/cancers14246127
- By:
- Publication type:
- Article
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design.
- Published in:
- 2013
- By:
- Publication type:
- journal article
A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer.
- Published in:
- Oncology, 2012, v. 82, n. 1, p. 25, doi. 10.1159/000335268
- By:
- Publication type:
- Article
Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY.
- Published in:
- Cancer Science, 2020, v. 111, n. 12, p. 4510, doi. 10.1111/cas.14655
- By:
- Publication type:
- Article
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
- Published in:
- Drug Safety, 2022, v. 45, n. 1, p. 45, doi. 10.1007/s40264-021-01127-2
- By:
- Publication type:
- Article
Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Treatment rationale and study design for a phaseIII, double-blind, placebo-controlled study ofmaintenance pemetrexed plus best supportivecare versus best supportive care immediatelyfollowing induction treatment with pemetrexedplus cisplatin for advanced nonsquamousnon-small cell lung cancer
- Published in:
- BMC Cancer, 2010, v. 10, p. 85, doi. 10.1186/1471-2407-10-85
- By:
- Publication type:
- Article